A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Ascrinvacumab (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 01 Nov 2016 Results published in the Journal of Thoracic Oncology
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 07 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014, as per ClinicalTrials.gov record.